The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: PARP inhibitors
Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
Activating “Inflammasome” May Improve Cancer’s Response To Immunotherapy And Parp Inhibitors
The inflammasome—a protein signaling network that is activated to rid the body of virus or bacteria-infected cells—may play an important role in triggering an immune response to cancer and causing an existing class of drugs to work better against cancers.
Building bridges: PARP enzymes bring broken DNA together
St. Jude researchers capture the structure of PARP enzymes at work, leading to a new understanding of DNA repair that may aid cancer treatments targeting the process.
PARP inhibitor becomes new treatment option for some men with advanced prostate cancer
Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib.